Day: December 3, 2024

Information on share capital and voting rights November 2024 Statement made in accordance with article L. 233-8 II of the French commercial Code and articles 221-1 2 ° f) and 223-16 of the AMF Regulations.                          December 3rd, 2024   Statement made by:         Nexans S.A.Registered office : 4 Allée de l’Arche – 92400 CourbevoieRCS Nanterre 393 525 852Regulated market of Euronext Paris (Compartment A)Date   Total number of shares   Total number of voting rightsTheorical (1) Exercisable (2)November 29th, 2024 43,753,380 43,753,380 43,597,572(1)   Calculated based on all shares with voting rights, including treasury shares stripped of voting rights (Art. 223-11 of AMF General Regulations). (2)    For information, excluding treasury shares stripped of voting rights, excluding liquidity...

Ms. Erdogan-Trinkaus brings a wealth of commercial leadership and expertise in sales and marketing from her tenure at leading global pharmaceutical companies and across the broader health and wellness sector, including significant experience in the pediatric endocrinology specialty.DEER PARK, Ill., Dec. 03, 2024 (GLOBE NEWSWIRE) — Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the appointment of Ipek Erdogan-Trinkaus as Chief Commercial Officer (CCO). Ms. Erdogan-Trinkaus brings to the Company broad commercial experience in the pharmaceutical industry, spanning leadership, sales, and marketing roles in both large and smaller organizations. She also brings valuable experience within...

GUANGZHOU, China, Dec. 03, 2024 (GLOBE NEWSWIRE) — Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it will hold its annual general meeting (“AGM”) on December 31, 2024 at 10:00 a.m. (local time) at the Company’s Shanghai office at 6/F, Building 10C, Pujiang Smart Plaza, No. 2168 Chenhang Highway, Minhang District, Shanghai. The notice of the AGM and the form of proxy for the AGM are available on the Company’s website, within Investors Relation section, at https://ir.brbiotech.com. The AGM will be held for the following proposals:as an ordinary resolution, THAT the appointment of Ernst & Young Hua Ming LLP as auditor of the Company for the fiscal year ending...

– CLICK will collaborate with Care U Professional Nursing Service Limited, being the first non-NGOs private company to become a licensed recognized service provider under the CCSV scheme, to provide integrated Home-based service for elderly under scheme in Hong Kong  – The CCSV scheme is a government-sponsored program that provides community care services through a “money-following-the-user” and “affordable users pay” subsidy model. Hong Kong, Dec. 03, 2024 (GLOBE NEWSWIRE) — Click Holdings Limited (“Click Holdings” or “we” or “our”, NASDAQ: CLIK) and its subsidiaries (collectively, the “Company”), signed a cooperation agreement with Care U Professional Nursing Service Limited (“Care U”) and agreed to jointly provide integrated Home-based service for elderly under the CCSV scheme in Hong Kong. The...

To Nasdaq Copenhagen                                    3 December 2024 Financial calendar 2025 for the companies of the Nykredit Group 5 FebruaryPublication of Annual Reports 2024 and announcements of Financial Statements of the Nykredit Realkredit Group, Totalkredit A/S (in Danish only) and the Nykredit Bank Group. 20 MarchAnnual General Meeting of Totalkredit A/S, Kalvebod Brygge 1-3, DK-1780 Copenhagen V. 20 MarchAnnual General Meeting of Nykredit Bank A/S, Kalvebod Brygge 1-3, DK-1780 Copenhagen V. 20 MarchAnnual General Meeting of Nykredit Realkredit A/S, Kalvebod Brygge 1-3, DK-1780 Copenhagen V. 8 MayPublication of Q1 Interim Report 2025 of the Nykredit Realkredit Group. 13 AugustPublication of H1 Interim Reports 2025 of the Nykredit Realkredit Group, Totalkredit A/S (in Danish only) and the Nykredit Bank Group. 6 NovemberPublication...

To Nasdaq Copenhagen                                3 December 2024 Financial calendar 2025 for the companies of the Nykredit Group 5 FebruaryPublication of Annual Reports 2024 and announcements of Financial Statements of the Nykredit Realkredit Group, Totalkredit A/S (in Danish only) and the Nykredit Bank Group. 20 MarchAnnual General Meeting of Totalkredit A/S, Kalvebod Brygge 1-3, DK-1780 Copenhagen V. 20 MarchAnnual General Meeting of Nykredit Bank A/S, Kalvebod Brygge 1-3, DK-1780 Copenhagen V. 20 MarchAnnual General Meeting of Nykredit Realkredit A/S, Kalvebod Brygge 1-3, DK-1780 Copenhagen V. 8 MayPublication of Q1 Interim Report 2025 of the Nykredit Realkredit Group. 13 AugustPublication of H1 Interim Reports 2025 of the Nykredit Realkredit Group, Totalkredit A/S (in Danish only) and the Nykredit Bank Group. 6 NovemberPublication...

VANCOUVER, British Columbia, Dec. 03, 2024 (GLOBE NEWSWIRE) — Fortuna Mining Corp. (NYSE: FSM | TSX: FVI) is pleased to report that during the fourth quarter as of Friday, November 29, 2024, it has repurchased under the Company’s normal course issuer bid (NCIB) an aggregate of 6,402,640 common shares on the open market of the New York Stock Exchange. Shares were repurchased at a weighted-average price of $4.77 per common share for a total gross amount of $30,529,066, excluding brokerage fees; these shares will be cancelled. To date, the Company has repurchased 41.88 percent of the 15,287,201 shares it is authorized to repurchase under the NCIB (refer to Fortuna news release dated April 30, 2024).   Jorge A. Ganoza, Chief Executive Officer of Fortuna commented, “With record earnings in the third quarter, and strong free cash flow...

Payment triggered by development milestone achieved by Regeneron’s collaborator in China, JW Therapeutics Progresses first clinical use of Medigene’s End-to-End Platform to generate potentially best-in-class TCRsPlanegg/Martinsried, December 3, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, today announced a USD $1 million milestone payment from Regeneron Pharmaceuticals, Inc. was triggered. Regeneron purchased the MAGE-A4-TCR program as part of its acquisition of 2seventy bio Inc.’s pre-clinical and clinical oncology and autoimmune cell therapy pipeline, which closed in April 2024. The payment was triggered by a development milestone for a trial in China led by JW Therapeutics...